9/17/2025 9:00 a.m. - 4:40 p.m. ET
9/18/2025 9:00 a.m. - 3:40 p.m. ET

The “Emerging Technologies for Coronary Artery Disease Imaging: Vision 2040” workshop will take place September 17–18, 2025, at the National Institutes of Health (NIH) campus in Bethesda, MD. This is an in-person workshop hosted by the National Heart, Lung, and Blood Institute and the National Institute of Biomedical Imaging and Bioengineering.

This workshop is dedicated to pinpointing the most promising *NEW* and emerging imaging technologies in the upcoming decade to elevate the landscape of coronary artery disease (CAD) imaging. Through this workshop, we aim to chart the trajectory of forthcoming CAD imaging advancements. The workshop will explore how these can radically change CAD patient management by leveraging cutting-edge imaging hardware, software, pioneering new probes, and integrating artificial intelligence (AI). Our goal is ambitious but achievable: to pioneer a screening instrument for CAD that is safe, efficient, and widely accessible; that can identify subclinical CAD; and that can dramatically reduce CAD-related morbidity and mortality rates by 2040.

The workshop will address the following questions:

1. How can we conceptualize a CAD screening tool analogous to mammography that boasts minimal radiation, ultra-high resolution, cost-efficiency, and is ubiquitously accessible? What guidelines might shape this mammography-like screening tool for subclinical CAD? What technological advancements are necessary to achieve this?
2. How will advancements in imaging technologies and methods improve and refine CAD measurements? How can enhanced imaging inform CAD interventions and treatments, and revolutionize patient management? That is, will earlier disease detection prompt or encourage earlier intervention?
3. How will data science propel our primary objective of screening subclinical CAD and measurably reduce CAD-related morbidity and mortality?
4. How can CAD imaging be established as a comprehensive and predictive biomarker in cardiovascular clinical trials?
5. How can we provide more accessible implementation and dissemination of CAD screening technologies?

Individuals requiring Sign Language Interpreters or other reasonable accommodations to facilitate their participation in this event should contact the workshop coordinator, Julia D'Albora, at jdalbora@seiservices.com at least five (5) days prior to the commencement of the event.